The Wingman, a new condom from the Netherlands, has won the iF Gold Award 2014. A price which is considered the highest international distinction, “the Oscar for product design.” Newcomer Wingman now joins a line of renowned winners such as Apple, Nokia, Philips and Porsche.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65018-condom-with-wings-wins-oscar-product-design
The start of this year’s football season brings an increased focus on protecting players at all levels from experiencing a concussion. With the abundance of today’s contact and extreme sports there is a lot of news about concussions, however, many of us do not know much about this common injury.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/59662-ochsner-health-systems-advice-for-athletes-as-they-head-back-to-school
To help combat an increasing trend in festive isolation, charity Abbeyfield today launches a nationwide campaign, Companionship At Christmas, to create an alternative to spending the celebratory period alone. The charity is offering free overnight stays and delicious Christmas lunches over the festive season (24th December – 4th January) in over 100 Abbeyfield sheltered houses and care homes. The Charity will take enquiries from now until December via their website or via their dedicated telephone number 0845 052 3553 up until the 18th December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58633-abbeyfield-launches-companionship-at-christmas-campaign
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
According to a National Safety Council poll released today, one in four Americans personally knows someone who has overdosed or died from an opioid overdose, knows someone who has become addicted to opioids, or has become addicted themselves. In response to the survey results – and a recommendation from the President’s Commission for Combating Drug Addiction and the Opioid Crisis – the National Safety Council is launching a provocative nationwide public education campaign that literally puts a face on the opioid epidemic. Stericycle is the Council’s exclusive disposal partner on the campaign.
To view the multimedia release go to:
https://www.multivu.com/players/English/8207151-national-safety-council-stop-everyday-killers-opioids/
Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis.
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Today, Colgate-Palmolive, in partnership with the Hispanic Dental Association (HDA), kicked off its annual Oral Health Month campaign with a special launch event at Los Angeles’s Plaza Mexico. To help raise awareness about the importance of a healthy smile, the Colgate Bright Smiles, Bright Futures® mobile dental van was on-site to provide bilingual learning materials and free dental screenings to children. Families in attendance also enjoyed a mariachi flash mob, live music and giveaways from local radio station, Univision 1020 AM.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7531451-colgate-oral-health-month/
Cochlear Limited, the global leader in implantable hearing solutions, has announced the launch of Nucleus® 6 in India, its next generation cochlear implant sound processor.
Nucleus 6 delivers industry first innovations designed to provide superior outcomes in a way that makes hearing a lot easier for the recipient – in the smallest sound processor on the market.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/63489-cochlear-announces-nucleus-6-system
Technology leader Samsung Electronics Co. Ltd., together with global health service company Cigna, today announced a new version of the Coach by Cigna mobile application that features the psychology of lateral assessment to identify your personality type, understands your wants, needs and preferences, and provides the right programs to help with diet, exercise, sleep, stress and weight.
Coach by Cigna is available at no charge in the Google Play store for Samsung Galaxy S6, S6 Edge, Galaxy S5, Galaxy Note 4 and Note Edge mobile devices.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7448831-coach-by-cigna-fitness-app/
Global health service company Cigna today announced it is expanding access to its popular Coach by Cigna health and fitness mobile application to make it more broadly available to its clients and customers. Coach is now available on both Apple® iOS and Android™ mobile smart devices.
Currently a go-to health and fitness app for more than 350,000 users in 15 nations in nine languages, Coach by Cigna is now available at no charge in the App Store ℠ and Google Play™ stores for mobile devices that have either the Apple® iOS9 or the Android™ Lollipop operating system.
To view the multimedia release go to:
http://www.multivu.com/players/English/7448831-coach-by-cigna-fitness-app/
